Bristol-Myers Squibb saw the highest growth of 111% in patent filings and 113% in grants in October in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 111% and grants by 113%. GlobalData’s DataBook provides a comprehensive analysis of Bristol-Myers Squibb‘s patent filings and grants. Buy the databook here.
Bristol-Myers Squibb has been focused on protecting inventions in United States(US) with 17 publications in Q4 2023
The United States(US) Patent Office dominates the patent filings and grants with nearly 55% filings and 100% grants. The United States(US), European Patent Office(EPO), and Australia(AU) patent Office are among the top ten patent offices where Bristol-Myers Squibb is filings its patents. Among the top granted patent authorities, Bristol-Myers Squibb has 100% of its grants in United States(US)
Johnson & Johnson and Pfizer could be the strongest competitors for Bristol-Myers Squibb
In terms of grant share, Bristol-Myers Squibb stands first among its competitors followed by Johnson & Johnson and Pfizer.
Lymphoma related patents lead Bristol-Myers Squibb portfolio followed by cell therapy, and multiple myeloma (kahler disease)
Bristol-Myers Squibb has highest number of patents in lymphoma followed by cell therapy, multiple myeloma (kahler disease), viral infections, and leukemia. For lymphoma, nearly 4% of patents were filed and 3% of patents were granted in Q4 2023.
For comprehensive analysis of Bristol-Myers Squibb's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.